Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used....

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Laios, Alexandros, Mohamed, Bashir M., Kelly, Lynne, Flavin, Richard, Finn, Stephen, McEvoy, Lynda, Gallagher, Michael, Martin, Cara, Sheils, Orla, Ring, Martina, Davies, Anthony, Lawson, Margaret, Gleeson, Noreen, D’Arcy, Tom, d’Adhemar, Charles, Norris, Lucy, Langhe, Ream, Saadeh, Feras Abu, O’Leary, John J., O’Toole, Sharon A.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: MDPI 2013
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3565367/
https://ncbi.nlm.nih.gov/pubmed/23340649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms14012085
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια